All News
Tofacitinib Efficacy in COVID-19 Pneumonia
NEJM has published the results of an observational trial wherein tofacitinib given to patients hospitalized with Covid-19 pneumonia, was shown to significantly lower risk of death or respiratory failure.
Read Article
Which patients with psoriasis are at risk to develop PsA?
The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.
Read Article
RheumNow Podcast - Speak Up! (6.18.2021)
Dr. Jack Cush talks on education, engagement and the challenge of speaking up, if not first!
Read Article
Do B-cell targeted therapies still have a place for the treatment of Sjogren’s?
B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy with rituximab in Phase II trials and case series, it failed to meet its primary endpoint when investigated in two Phase III trials. It is worth noting that the primary endpoint used in both trials was a subjective measure. Post-hoc analyses however showed greater improvement in objective measures such as salivary flow rate and salivary gland ultrasound score in RTX-treated group vs placebo.
Therefore, do B-cell targeted therapies still have a place for the treatment of pSS?
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links: